These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26056589)

  • 1. Relevance of Wnt signaling for osteoanabolic therapy.
    Yorgan TA; Schinke T
    Mol Cell Ther; 2014; 2():22. PubMed ID: 26056589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
    Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
    J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
    Levasseur R; Lacombe D; de Vernejoul MC
    Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
    Ferrari SL; Deutsch S; Antonarakis SE
    Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
    J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.
    Haÿ E; Laplantine E; Geoffroy V; Frain M; Kohler T; Müller R; Marie PJ
    Mol Cell Biol; 2009 Feb; 29(4):953-64. PubMed ID: 19075000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
    Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
    Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
    Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
    J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation.
    Haÿ E; Buczkowski T; Marty C; Da Nascimento S; Sonnet P; Marie PJ
    J Bone Miner Res; 2012 Sep; 27(9):1852-63. PubMed ID: 22576936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the Wnt signaling pathway in osteoblast commitment and differentiation.
    Yavropoulou MP; Yovos JG
    Hormones (Athens); 2007; 6(4):279-94. PubMed ID: 18055419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.
    Korvala J; Jüppner H; Mäkitie O; Sochett E; Schnabel D; Mora S; Bartels CF; Warman ML; Deraska D; Cole WG; Hartikka H; Ala-Kokko L; Männikkö M
    BMC Med Genet; 2012 Apr; 13():26. PubMed ID: 22487062
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Yadav PS; Feng S; Cong Q; Kim H; Liu Y; Yang Y
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34172578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cajanolactone A from
    Liu S; Luo ZH; Ji GM; Guo W; Cai JZ; Fu LC; Zhou J; Hu YJ; Shen XL
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30642055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomerization of Frizzled and LRP5/6 protein initiates intracellular signaling for the canonical WNT/β-catenin pathway.
    Hua Y; Yang Y; Li Q; He X; Zhu W; Wang J; Gan X
    J Biol Chem; 2018 Dec; 293(51):19710-19724. PubMed ID: 30361437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
    Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
    J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
    Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
    Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wnt signaling and osteoblastogenesis.
    Bodine PV; Komm BS
    Rev Endocr Metab Disord; 2006 Jun; 7(1-2):33-9. PubMed ID: 16960757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRPs in WNT Signalling.
    Davidson G
    Handb Exp Pharmacol; 2021; 269():45-73. PubMed ID: 34490514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRP5, Bone Mass Polymorphisms and Skeletal Disorders.
    Littman J; Yang W; Olansen J; Phornphutkul C; Aaron RK
    Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.